Goldman Sachs raised the firm’s price target on TG Therapeutics (TGTX) to $39 from $37 and keeps a Neutral rating on the shares. The firm says the stock is expected to trade higher after the company’s disclosure of 2026 revenue guidance of $875M-$900M abd with Phase 3 enrollment for the subcutaneous form of BRIUMVI program advancing ahead of expectations, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX: